412 Mt. Kemble Avenue
We are here to make a Meaningful Difference. It is the foundation of the way we do business. Looking after our people, our customers, our planet is core to our purpose. A career at Lonza is more than a job. We do not just work in the life sciences industries, we are transforming it. What we do today is helping to create a healthier, happier world tomorrow. That’s the meaningful difference we make every day.
We are dedicated to science. We apply our industry knowledge to pioneer cell therapy, and the medicines of tomorrow. Our work enables our customers to protect millions of people from illness and disease. While we work in science, there’s no magic formula to how we do it. Our greatest scientific solution is talented people working together, devising ideas that help our customers. In exchange, we let our people drive their own careers. Because their commitment and ideas, big and small, genuinely improve the world, and that’s the kind of work we want to be part of. Our work makes a Meaningful Difference.
Brand New released EVP video "A Meaningful Difference"
204 articles with Lonza
Humanigen and Lonza Announce Collaboration to Expand Manufacturing of Humanigen's COVID-19 Therapeutic Candidate Lenzilumab
In an effort to change the course of this pandemic, advancing lead COVID-19 therapeutics requires matched supply chain efforts and expertise to meet the continued and urgent patient needs.
IsoPlexis and Lonza Collaborate to Enable the Next Generation of Precision Cell Therapy Manufacturing
- Lonza to utilize of IsoPlexis' IsoLight® automated proteomics platform - IsoLight® to be used for functional quality analytics for cell therapy products produced on Lonza's Cocoon® Platform, an automated cell manufacturing platform [20-August-2020] BASEL, Switzerland and BRANFORD, Conn. , Aug. 20, 2020 /PRNewswire/ -- Quote from Matthew Hewitt , Hea
Anthos Therapeutics Partners with Lonza to Develop and Manufacture Abelacimab (MAA868), a Unique Dual Factor XI / XIa inhibitor
The agreement furthers Anthos Therapeutics mission to develop Abelacimab for patients at risk of thrombotic events, which are currently underserved by conventional anti-coagulant therapies.
Moderna and Lonza Announce Worldwide Strategic Collaboration to Manufacture Moderna’s Vaccine (mRNA-1273) Against Novel Coronavirus
Moderna, Inc., a clinical stage biotechnology company pioneering messenger RNA therapeutics and vaccines to create a new generation of transformative medicines for patients, and Lonza Ltd. announced a 10-year strategic collaboration agreement to enable larger scale manufacture of Moderna’s mRNA vaccine against the novel coronavirus and additional Moderna products in the future.
As the situation progresses, they hope to establish more production suites across Lonza’s facilities globally, with a goal of manufacturing up to 1 billion doses of mRNA-1273 per year at the currently expected dose of 50 µg.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 1, 2020.
XORTX Appoints Lonza for GMP Manufacturing and Formulation of XRx-101 (Oxypurinol) for Coronavirus / COVID-19 Clinical Trials
XORTX Therapeutics Inc., a biopharmaceutical company focused on developing innovative therapies to treat kidney disease announces that it has granted the manufacturing contract for the active pharmaceutical ingredient for XRx-101 and XRx-008 to Lonza Pharma & Biotech.
Free Lonza webinar to discuss the benefits of using physiologically relevant 3D cell culture models to enhance respiratory research for diseases like COVID-19
Lonza Launches New TheraPEAK™ SfAAV™ Medium to Boost and Optimize the Production of AAV in Sf9 Insect Cells
Lonza has launched a new medium to enhance and accelerate the production of Adeno Associated Virus (AAV) in Spodoptera Fuigiperda (Sf9) insect cells
Triumvira Immunologics and Lonza Announce Collaboration to Develop Innovative Point-of-Care Manufacturing for TAC T-Cell Therapeutic Targeting Solid Tumors
Collaboration between Triumvira Immunologics and Lonza will leverage the innovative Cocoon® Platform for novel TAC01-HER2 program
Lonza Collaborates with Immunotherapy Leaders to Assess Point-of-Care Manufacturing for Cancer Cell Therapies
“We are extremely motivated to be working hand-in-hand with these premier institutes, among the leaders in cell-based immunotherapy discovery and development, to exhibit the use of the closed, automated Cocoon® Platform for manufacturing cell therapies.
Albert Baehny, chairman of the board of directors, said the company looks forward to the coming challenges of 2020, including the naming of a new CEO.
Lonza’s New eCHO™ Basal Medium and Feed Facilitates Late-Stage Cell Viability and a Consistent Yield of High Integrity Proteins
Results demonstrating the performance of the eCHO™ Medium will be presented at the 2019 PEGS Europe and Antibody Engineering and Therapeutics conferences
Lonza announced that Marc Funk, CEO, will leave the Company for personal reasons. The Board of Directors also announced that Albert Baehny, Chairman, will take on the additional responsibility of Chief Executive Officer on an ad interim basis until a permanent successor is found.
Lonza Partners with Cryoport and Strengthens its 'Vein-to-vein' Delivery Network in Cell & Gene Therapy
Cryoport as a preferred partner for Lonza in the transport and delivery of patient tissues on a global basis
Lonza to Host New Webinar – “Paper to EBR in 9 Months: How a Strong Collaboration Leads to Project Success”
Free Lonza webinar to discuss the benefits of a collaborative approach to implementing an Electronic Batch Record Platform
Mesoblast and Lonza Enter Into Agreement for Commercial Manufacture of Mesoblast’s Potential First United States Allogeneic Cell Therapy
Mesoblast and Lonza announced that they have entered into an agreement for commercial manufacture of Mesoblast’s lead allogeneic cell therapy product candidate, remestemcel-L for pediatric steroid-refractory acute graft versus host disease
Lonza’s Ibex™ Design planned to take Genmab’s pre-clinical candidates from gene to potential IND within 12 months
The two companies will partner on the process development, analytical development and large-scale manufacturing for late-stage clinical and commercial supply.
Lonza’s MODA-ES™ Platform helps Nephron Pharmaceuticals move from paper to an EBR in nine months – Case study to be presented at 2019 ISPE Annual Meeting
Lonza has partnered with Nephron Pharmaceuticals Corporation to implement Lonza’s next-generation MODA-ES™ EBR Platform to streamline manufacturing compliance reporting